Summary
Boston Scientific Corporation's 2019 10-K filing highlights a year of robust growth, driven significantly by strategic acquisitions, most notably BTG plc. The company reported net sales of $10.735 billion, an increase of 9.3% over the prior year, with operational growth of 11.1%. This growth was broadly distributed across its key segments, including Cardiovascular and MedSurg, with notable contributions from product launches and advancements in structural heart therapies and peripheral interventions. The company's financial performance was impacted by various charges and credits, including acquisition-related costs and a significant deferred tax benefit related to intellectual property transfers, resulting in a reported net income of $4.700 billion. Management, however, emphasizes adjusted net income of $2.234 billion for a clearer view of underlying operational performance. Boston Scientific's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, supported by continued investment in research and development. The company maintains a strong balance sheet and adequate liquidity, though it navigates an evolving healthcare landscape with pricing pressures and regulatory changes, particularly the upcoming EU MDR implementation.
Financial Highlights
54 data points| Revenue | $10.73B |
| Cost of Revenue | $3.12B |
| Gross Profit | $7.62B |
| SG&A Expenses | $3.94B |
| Operating Expenses | $6.10B |
| Operating Income | $1.52B |
| Interest Expense | $473.00M |
| Net Income | $4.70B |
| EPS (Basic) | $3.38 |
| EPS (Diluted) | $3.33 |
| Shares Outstanding (Basic) | 1.39B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1Net sales reached $10.735 billion in 2019, up 9.3% from 2018, with strong operational growth of 11.1%.
- 2The acquisition of BTG plc in Q3 2019 significantly contributed to growth, particularly in the Peripheral Interventions segment.
- 3Key product areas like Structural Heart Therapies (WATCHMAN, ACURATE valves) and Peripheral Interventions (Eluvia stent) showed strong performance.
- 4Reported net income was $4.700 billion, benefiting from a $4.1 billion deferred tax benefit related to intellectual property transfers, while adjusted net income was $2.234 billion.
- 5The company maintained a strong liquidity position with $1.836 billion in cash provided by operating activities in 2019 and $217 million in cash and cash equivalents at year-end.
- 6The company continued to invest in R&D, with expenses increasing 6% to $1.174 billion, underscoring its commitment to innovation.
- 7Total debt increased to $10.008 billion from $7.056 billion in the prior year, largely due to financing activities related to acquisitions.